Multi-targeted tyrosine kinase inhibitor reverses resistance to immunotherapy in hepatic sarcomatoid carcinoma.

Chen, Juan; Chen, Wenjuan; Qu, Xiujuan; Chen, Ying

Chen, Juan; Chen, Wenjuan; Qu, Xiujuan; Chen, Ying.

Afiliación

Chen J; Department of Medical Oncology, The First Hospital of China Medical University, No. 155 Nanjing North Street, Heping District, Shenyang, Liaoning, China.
Chen W; Department of Medical Oncology, The First Hospital of China Medical University, No. 155 Nanjing North Street, Heping District, Shenyang, Liaoning, China.
Qu X; Department of Medical Oncology, The First Hospital of China Medical University, No. 155 Nanjing North Street, Heping District, Shenyang, Liaoning, China. xjqu@cmu.edu.cn.
Chen Y; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China. xjqu@cmu.edu.cn.

J Cancer Res Clin Oncol ; 149(20): 17849-17853, 2023 Dec.

Article en En | MEDLINE | ID: mdl-37943357

Asunto(s)

Carcinoma de Células Renales; Carcinoma; Neoplasias Renales; Humanos; Persona de Mediana Edad; Carcinoma de Células Renales/patología; Neoplasias Renales/patología; Receptor de Muerte Celular Programada 1; Calidad de Vida; Inhibidores de Proteínas Quinasas/farmacología; Inhibidores de Proteínas Quinasas/uso terapéutico; Inmunoterapia

Palabras clave

Antiangiogenic therapy; Efficacy; Hepatic sarcomatoid carcinoma; Immunotherapy; Liver sarcomatoid carcinoma; Tyrosine kinase inhibitors

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma / Carcinoma de Células Renales / Neoplasias Renales Límite: Humans / Middle aged Idioma: En Revista: J Cancer Res Clin Oncol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Alemania

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google